Get 40% Off
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas toolCopy Portfolio

Analog Devices (ADI) To Report Q1 Earnings: What's In Store?

Published 02/17/2020, 06:20 AM
Updated 07/09/2023, 06:31 AM
ADI
-
TXN
-
MXIM
-
AVGO
-
AAOI
-
SQ
-

Analog Devices, Inc. (NASDAQ:ADI) is slated to report first-quarter fiscal 2020 results on Feb 19, before the opening bell. In the last reported quarter, it delivered a negative earnings surprise of 1.7%.

The company topped the Zacks Consensus Estimate in three out of the trailing four quarters, recording an average of 2.5%.

Trend in Estimate Revision

For the fiscal first quarter, the Zacks Consensus Estimate for earnings has remained stable at $1.00 per share over the past 30 days. This indicates a decline of 24.8% from the year-ago reported figure.

Notably, the consensus mark for revenues is pegged at $1.30 billion, implying a decline of 15.6% from the year-ago reported figure.

Let’s see how things have shaped up for this announcement.

Analog Devices, Inc. Price and EPS Surprise

Factors to Note

Analog Devices has been benefiting from strength in industrial, automotive, consumer and communications markets, along with increased focus on innovation and operational execution.

The automotive electronics market is likely to have gained from consumer demand for added technology and features in new vehicles, along with the transition to hybrid and electric vehicles. The Zacks Consensus Estimate for automotive revenues is pegged at $205 million.

The communications market is anticipated to have performed well in the quarter to be reported, driven by strength in the wireless segment. The accelerated build out of TD-LTE in China, continuing 5G network densification activities in the United States and deployments in Europe benefited the communications segment. The Zacks Consensus Estimate for communications is pegged at $256 million.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

However, softness in the consumer market might have been a major concern. Also, macroeconomic headwinds and geopolitical uncertainty are likely to have remained overhangs during the quarter. Further, rising competitive pressure from Maxim (NASDAQ:MXIM) and Texas Instruments (NASDAQ:TXN) may reflect on its upcoming results.

For the fiscal fourth quarter, the Zacks Consensus Estimate for revenues from industrial and consumer is pegged at $662 million and $174 million, respectively.

What Our Model Says

Our proven model does not conclusively predict an earnings beat for Analog Devices this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That is not the case here as you will see below.

Earnings ESP: The company has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

Zacks Rank: Currently, Analog Devices has a Zacks Rank #4 (Sell).

Stocks That Warrant a Look

Here are a few stocks worth considering, as our model shows that these have the right combination of elements to deliver an earnings beat in the upcoming releases.

Broadcom Inc. (NASDAQ:AVGO) has an Earnings ESP of +1.72% and a Zacks Rank of 2.

Square Inc. (NYSE:SQ) has an Earnings ESP of +3.59% and a Zacks Rank #3.

Applied Optoelectronics, Inc. (NASDAQ:AAOI) has an Earnings ESP of +8.12% and a Zacks Rank of 3. You can see the complete list of today’s Zacks #1 Rank stocks here.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>



Analog Devices, Inc. (ADI): Free Stock Analysis Report

Broadcom Inc. (AVGO): Free Stock Analysis Report

Applied Optoelectronics, Inc. (AAOI): Free Stock Analysis Report

Square, Inc. (SQ): Free Stock Analysis Report

Original post

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.